Program for Treatment of Hematological Malignancies (PETHEMA) LPA-96, designed for the treatment of acute promyelocytic leukemia (APL), cDNA samples obtained by reverse transcription of RNA from bone marrow samples of patients with APL were sent to participating laboratories. During the first year of this external quality assessment trial nine samples were tested by a maximum of 12 laboratories. The control gene was satisfactorily amplified in 90% of the samples (62 of 69 samples), supporting the adequacy of the cDNA to be used as control sample. There was an 83% concordance between laboratories for PML/RAR␣ detection with similar results for the type of PML/RR␣ rearrangements. However, 17% disagreement still remained, attributable to low sensitivity or inadequacy of methods followed. The results stressed the need for implementation of an external quality assessment scheme to ensure the standardization of the results.
Introduction
The widespread use of RT-PCR methods for molecular detection of onco-hematological gene rearrangements and to monitor the presence of minimal residual disease (MRD), requires standardization to achieve the reproducibility, simplicity and robustness that clinical demands require. Despite the widespread use of PCR in molecular laboratories, programs of external quality assurance by which individual laboratories can assess and directly compare the performance of their respective RT-PCR methods are not available. To our knowledge there are a few external quality assurance schemes for PCR methods, 1 mostly in the field of microbiology tests, [2] [3] [4] [5] to our knowledge none to control the molecular detection of onco-hematological gene rearrangements.
With the intention of studying the standardization of the results obtained in PML/RAR␣ RT-PCR detection by laboratories in hospitals involved in the Spanish Program for Treatment of Hematological Malignancies (PETHEMA) LPA-96 designed for the treatment of acute promyelocytic leukemia (APL), cDNA samples obtained by reverse transcription of RNA from bone marrow samples of patients with APL were sent to participating laboratories.
During the first year of this external quality assessment trial two rounds of samples were tested, four samples and seven participating laboratories in the first, and five samples and 12 laboratories in the second. The control gene was satisfactorily amplified in 90% of the samples (62 of 69 samples), supporting the adequacy of the cDNA to be used as control sample. With regard to PML/RAR␣ gene detection, there was 83% agreement between laboratories and similarly with the classification of PML/RAR␣ rearrangements. However, 17% disagreement still remained, attributable to low sensitivity of methods or to the inadequacy of the procedures followed.
The results indicate that PCR methods are not yet standardized, suggesting the need for implementation of an external quality assessment scheme with regular participation of the laboratories involved to ensure the standardization of their results.
Materials and methods

Program design
The co-ordinating laboratory (Laboratorio de Biologίa Molecular, Hospital Universitario La Fe, Valencia, Spain) assigns a code to each of the participating laboratories and keeps a record of the methods, reagents and equipment use to detect PML/RAR␣ rearrangements. The co-ordinating laboratory also collects the cDNA control samples prepared by the participating laboratories (see sample control preparation) and is in charge of shipping control samples to the participating laboratories, collecting the results obtained, and of elaborating statistical reports summarizing the results at the end of each shipment.
Participating laboratories
A maximum of 12 laboratories participated in the program, 10 in the first shipment (the results of two of them were excluded because they were having methodological problems at the time of the analysis) and 12 in the second. The majority of laboratories (10 out of 12) belonged to different Spanish public hospitals, including the co-ordinating laboratory which also participates in the program. Two foreign laboratories also took part in the program.
Type of control samples
Most control samples used were cDNAs obtained by reverse transcription of RNA extracted from bone marrow (BM) samples of APL patients, however a sample of cDNA from NB4 cell line and a water sample (reagent control) were also included (Table 1) . Although no negative PML/RAR␣ sample was included in the two shipments described here, in the third shipment, a sample from a patient with chronic myeloid leukemia (CML) was analyzed (data not shown). After the deadline period fixed for each shipment was met, the laboratories which had prepared the cDNA control samples, informed the co-ordinating laboratory of the samples they sent and type of PML/RAR␣ rearrangement detected (Table 1) .
Sample preparation
Participating laboratories were responsible for preparing the cDNA control sample the month before shipment. Each cDNA was prepared from 1 g RNA of a single patient/sample using Moloney murine leukemia virus (M-MLV) reverse transcriptase and either a random primer or the antisense RAR␣ primers used in the first PCR, in the final volume and protocol conditions of the participating laboratories. The laboratories performed the necessary transcriptions to prepare a number of aliquots equal to the number of participating laboratories with a minimum volume of 12 l (sufficient for testing each sample at least once). These aliquots were distributed in Eppendorf tubes with no markings to avoid identification and they were kept frozen at −20 or −80°C. An arbitrary aliquot was tested for the PML/RAR␣ rearrangement by the same laboratory and then the aliquots were sent in dry ice to the co-ordinating laboratory where they were kept frozen at −40°C until four to five samples from different patients were collected. The control samples were numbered successively once received by the co-ordinating laboratory.
Shipments
During 1997, the co-ordinating laboratory made two shipments. In the first shipment, four samples were sent to all laboratories and in the second, five. The participating laboratories received the numbered controls and two forms, one to complete with the incidences of the delivery, and the other to fill in the test results (control gene, qualitative results of PML/RAR␣ rearrangement and type of rearrangement: bcr1, bcr2, bcr1-2 or bcr3). The time period to perform sample analysis and the mailing/faxing of test results to the co-ordinating laboratory was of approximately 1 month. The control samples were packaged in a styrofoam box containing sufficient dry ice to keep the cDNA samples frozen for the duration of delivery, at least 24 h.
Criteria for result acceptability
The results provided by the participating laboratory which prepared the sample were accepted as the expected result for the control samples assuming that it agreed with the majority of participating laboratories with regard to the control gene, PML/RAR␣ rearrangement and type of rearrangement. In the case of open contradictions the results of the control sample were excluded.
Results and discussion
Methods used by participating laboratories
Eight of the 12 laboratories (66%) followed the PCR methods of Lo Coco et al 6 or Biondi et al 7 two (16%) Borrow et al, and the two remaining followed the method of either Huang et al 9 or Castainge et al. 10 Six out of 12 laboratories (50%) used Perkin Elmer 2400 or 9600 thermocyclers (Norwalk, CT, USA), four (33%) MJ Research PTC-100 (Watertown, MA, USA), and the two remaining laboratories used a Perkin Elmer Cetus DNA and a Linus 32 (Barcelona, Spain).
Four of the 12 laboratories (33%) used the specific AmpliTaq Gold (Perkin-Elmer, Roche Molecular Systems, Branchburg, NJ, USA) in which the hot-start is implicit. Two utilized the Perkin-Elmer Taq, three (25%) Boehringer Mannheim Taq (Penzburg, Germany), two Promega Taq (Madison, WI, USA) and one laboratory Ecotaq (Ecogen).
Nine of 11 laboratories used RAR␣ as the control gene, and the two remaining employed either ABL or AML. In all cases, the amplification of the control gene was carried out in a single round of PCR.
Results obtained Control gene:
In the first shipment, all laboratories were able to amplify the control gene in samples 1 and 3, and nearly all laboratories detected the control gene in sample 2 ( Figure 1) . However, for sample 4, only two of the six laboratories which tested this sample amplified the control gene and another catalogued the result as non-valuable, data that suggest poor quality cDNA.
In the second shipment, with the exception of sample 9, nine of 11 laboratories classed the control gene as negative with regard to its water content, the rest of the samples in this shipment (5 to 8) were catalogued as positive for the control gene for most participating laboratories (Figure 1 ). Another aspect that should be commented on is that in this second shipment, the two laboratories that used AML or ABL as the control gene were able to detect control gene expression in samples 5 and 7 in spite of the fact that their cDNA was obtained using an antisense RAR␣ as primer for reverse transcription. This suggests that the conditions usually used for primer annealing in reverse transcription were not stringent enough to avoid non-specific hybridization, although contamination problems cannot be ruled out. The control gene was detected by almost all the participating laboratories in nearly all the samples analyzed, with the exception of samples 4 and 9 that contained distilled water. If sample 4 is excluded according to the criteria of acceptability it can be concluded that the cDNA samples used in this study are stable enough to be used as controls, always provided that they were kept frozen at −20°C and tested within 1-2 months from their preparation.
PML/RAR␣ rearrangement:
In the first shipment, seven participating laboratories coincided in classing samples 1 and 3 as positive for PML/RAR␣ rearrangement (Figure 2) , and the majority of laboratories (5 of 7, Figure 2 ) catalogued sample 2 as positive. It should be pointed out that of the two laboratories which failed to detect PML/RAR␣ rearrangement in sample 2, one of them, the same that had prepared this cDNA sample, tested the sample following Lo Coco's method 6 but using only the external M4/R5-R8 primers that cover types bcr3 or bcr1-2. However, the other laboratories that followed the same method using inner primers that distinguished types bcr1 and bcr2 (M2/R5-R8), were able to detect the rearrangement. This observation stresses the need to recommend to the laboratories that followed the methods of Lo Coco 6 or Biondi, 7 the systematic use of both primers, M4/R5-R8 and M2/R5-R8, to test any unknown samples in order to avoid false negative results. Sample 4 was classified as negative by the three laboratories that catalogued the control gene as positive and by the one that catalogued it as non-valuable. The laboratories that were unable to amplify the control gene catalogued the control sample as non-valuable (Figure 2 ).
In the second shipment, agreement was observed for control samples 5, 6, 8 and 9. Control samples 5, 6 and 8 were catalogued as positive by all (sample 6) or nearly all (samples 5 and 8) participating laboratories (Figure 2 ). Sample 9 was classed as negative by most of the laboratories (11/12, Figure  2 ), corresponding to its distilled water content. However, the results obtained for sample 7 covered the entire range of possibilities: five laboratories classed it as positive, five as negative and two as non-valuable. The discrepancies observed for sample 7 (LPA patient in complete remission) could not be attributed to the cDNA transcription, since the majority of laboratories were able to amplify the control gene, but probably to the low sensitivity of the methods to detect the low amount of transcripts supposed to be present in a sample of a patient in complete remission.
Classification of the rearrangements:
In the first shipment, all or most of the participating laboratories classed control samples 1 and 3 either as bcr1, for laboratories that followed the methods of Lo Coco et al 6 or Biondi et al, 7 or its equivalent bcr1-2, for those others that used the Borrow et al method 8 ( Figure 3) . The results of sample 2 are in agreement with those described for PML/RAR␣ rearrangement, where the two laboratories that could not detect PML/RAR␣ rearrangement were consequently unable to evaluate the type of rearrangement (Figure 3) . Sample 4 was catalogued as negative or non-valuable by nearly all laboratories with the exception of a single laboratory that classed it as bcr3 (Figure 3) .
In the second shipment of control samples, good agreement of the type of rearrangements for control samples 5, 6, 8 and 9 was observed. Samples 6 and 8 were classed as bcr3 by all (sample 6) or nearly all (sample 8) participating laboratories. Nearly all laboratories (11 of 12, Figure 3 ) that followed the Lo Coco et al 6 or Biondi et al 7 methods coincided in classifying sample 5 as bcr1, or its equivalent of bcr1-2 by the others using Borrow's method. 8 There is complete agreement in classifying control sample 9 as negative, in accordance with its distilled water content. However, there was a complete spectrum of possibilities for the type of rearrangement for sample 7: seven laboratories classed it as non-valuable, three as bcr3, and two as bcr1 or bcr2, in agreement with the results obtained for PML/RAR␣ detection ( Figure 3 ). The broad discrepancy of results observed for sample 7 could be related to the limited amounts of transcripts supposed to be present in the sample corresponding to an APL patient in complete remission.
Compliance of results obtained with data reported by laboratories providing cDNA samples:
Nineteen of the 27 results received in the first shipment (70%) agreed with the data reported by laboratories that prepared control samples, but the levels of agreement increased up to 85% (18 coincidences of 21 results) if control sample 4 was excluded for being non- valuable since most laboratories failed to amplify the control gene according to the established criteria of acceptability (Table 1) .
In the second shipment, 49 of the 60 results received agreed with those reported by laboratories that prepared control samples (82%) and this percentage increased to 96% (46 coincidences of 48 results) if sample 7 was excluded. The main discrepancies were observed in sample 7 and minor discrepancies in samples 5 and 8 ( Table 1) .
The degree of agreement of the data of both shipments with the results of the laboratories that prepare the samples is only 78% (68 coincidences of 87 results) when considering all the results, but when we exclude sample 4 it increases up to 83% (67 coincidences of 81 results). Although the final goal is to reach 100% agreement in PML/RAR␣ detection in samples at diagnosis, the figure of 83% obtained here is acceptable, considering that we introduced a further degree of refinement if we consider the agreement with the type of rearrangement. Moreover, if it were patient samples instead of controls, the possibility of repeating a second aliquot or sample would be advisable and possible, but it is not feasible for control samples due to the limited amount of cDNA. However close to 17% error in the classification was still observed due to classification errors in sample 7 and minor discrepancies in control sample 2, in this case caused by inappropriate use of primers by laboratories following the method of Lo Coco et al 6 or Borrow et al. 8 
Commentaries and conclusions
The importance of regular exchange of samples between laboratories or regular participation in an external quality control program is supported by the fact that one laboratory was able to detect a methodological problem in the classification of the rearrangement thanks to its taking part in this program.
The results of the present study indicate that PCR methods used are not yet standardized and thereby reinforces the need for multicenter studies to compare methods and to ensure that laboratories are able to provide a PCR test of the quality and technical accuracy required in clinical practice.
Perspectives
Because of the positive results obtained with the cDNA samples, we decided to make progress in the control of reverse transcription by planning the inclusion of an RNA control sample for the next shipment and to include a sensitivity study making several dilutions of the NB4 cell line in normal peripheral blood mononucleated cells.
